Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Executive summary RGA has quantified the expected mortality and morbidity impacts of incretin-based drugs, including GLP-1s, approved as anti-obesity medications (AOMs) and diabetes treatments in the US, UK, Canada, and Hong Kong
As the range of options expands but prices vary from provider to provider, companies like GLP Winner are also emerging to help patients find the right provider for their needs
DOI: Published online: April 25, 2016 Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
RS-2024-00406568)
US$ 24.78
US$ 27.07
US$ 23.97
US$ 25.37
US$ 27.83
US$ 28.80
US$ 25.15
US$ 23.70
